youtube
Medicare has launched a new bridge program offering GLP-1 weight loss drugs to seniors for just $50 a month, a major policy shift projected to add over $1 billion in annual revenue for Eli Lilly ($LLY) and Novo Nordisk ($NVO). In this video, we break down the institutional data: Eli Lilly's massive 82.83% gross margin, its $72.2 billion in total revenue, and why the Seeking Alpha Quant rating remains a 'Hold' despite surging demand. With Wall Street projecting the global weight loss market to reach $150 billion by the end of the decade, discover how these pharmaceutical giants are positioned for long-term growth.
|
